Pilot study of CD147 protein expression in epithelial ovarian cancer using monoclonal antibody 12C3

Aim:  CD147 is a membrane glycoprotein that is expressed in various cancer cells and is involved in tumor invasion and metastasis by inducing stromal fibroblastic cells to produce matrix metalloproteinases. This study was carried out to evaluate the correlation between CD147 expression and various clinicopathologic parameters, including histological grade and prognosis in a small sample set of human ovarian cancer patients.

[1]  Yong Li,et al.  Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression , 2010, Clinical & Experimental Metastasis.

[2]  D. Millimaggi,et al.  Vasculogenic mimicry of human ovarian cancer cells: role of CD147. , 2009, International journal of oncology.

[3]  V. Kosma,et al.  Prognostic Significance of Extracellular Matrix Metalloproteinase Inducer and Matrix Metalloproteinase 2 in Epithelial Ovarian Cancer , 2007, Tumor Biology.

[4]  E. Oliva,et al.  Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences , 2007, The American journal of surgical pathology.

[5]  Hiroyuki Takahashi,et al.  Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. , 2007, Oncology reports.

[6]  K. Tsuneyama,et al.  Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis , 2006, British Journal of Cancer.

[7]  H. Iwasaki,et al.  Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression , 2006, Pathology international.

[8]  G. Fleuren,et al.  EMMPRIN‐induced MMP‐2 activation cascade in human cervical squamous cell carcinoma , 2006, International journal of cancer.

[9]  Jong-Shiaw Jin,et al.  Increasing Expression of Extracellular Matrix Metalloprotease Inducer in Ovary Tumors: Tissue Microarray Analysis of Immunostaining Score With Clinicopathological Parameters , 2006, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[10]  P Maisonneuve,et al.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[11]  M. Urashima,et al.  CD147 and matrix metalloproteinase‐2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma , 2004, Cancer.

[12]  G. Sauter,et al.  Expression of Extracellular Matrix Metalloproteases Inducer on Micrometastatic and Primary Mammary Carcinoma Cells , 2004, Clinical Cancer Research.

[13]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[14]  R. Hornung,et al.  Analysis of potential prognostic factors in 111 patients with ovarian cancer. , 2004, Cancer letters.

[15]  A. Berner,et al.  EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma , 2004, Clinical & Experimental Metastasis.

[16]  R. Cress,et al.  Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. , 2003, Gynecologic oncology.

[17]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[18]  K. Syrjänen,et al.  P53 and Bcl‐2 as prognostic predictors in epithelial ovarian cancer , 2002, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[19]  J. Diebold,et al.  Grading of Ovarian Carcinomas , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  R. Kreienberg,et al.  p53 mutations and expression in ovarian cancers: correlation with overall survival. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[22]  S. Silverberg.  Toward the development of a universal grading system for ovarian epithelial carcinoma. , 1999, Gynecologic oncology.

[23]  Y. Taketani,et al.  Patients with ovarian carcinoma upstaged to Stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients , 1998, Cancer.

[24]  M. Morgan,et al.  Clinical characteristics of clear cell carcinoma of the ovary. , 1998, Gynecologic oncology.

[25]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. , 1998, Gynecologic oncology.

[26]  N. Sakuragi,et al.  Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. , 1998, International journal of cancer.

[27]  B. Miedema,et al.  High mortality after abdominal operation in patients with large‐volume malignant ascites , 1996, Journal of surgical oncology.

[28]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[29]  C. Fisher,et al.  Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment , 1994, International Journal of Gynecologic Cancer.

[30]  E. Felip,et al.  Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. , 1994, Gynecologic oncology.

[31]  M. Brady,et al.  Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.

[32]  J. Carstensen,et al.  Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. , 1993, Gynecologic oncology.

[33]  K. Bertelsen.  Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. , 1990, Gynecologic oncology.

[34]  C A SALVATORE,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.